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Background  
Atopic dermatitis (AD) is a chronic disease negatively impacting patients (physically and psychologically), 
society, and the healthcare system.  Although the etiology of AD is complex, pruritis is present in most 
cases and contributes significantly to decreased Quality of Life (QoL).  Focus on the inflammatory 
pathway and the role of phosphodiesterase (PDE) led to the development of Crisaborole, the first topical 
anti-inflammatory agent for AD in 15 years and approved Dec. 2016.  Although other topical agents, 
corticosteroids and calcineurin inhibitors, are effective, safety concerns inhibit consistent use.   Given 
the positive benefit/risk ratio of Crisaborole demonstrated in clinical trials, we conducted a literature 
review to explore the effect of Crisaborole on patient QoL associated with mild to moderate atopic 
dermatitis.    
Methods 
A search for “Crisaborole and QoL” in “Journal Articles” in PubMed and Embase resulted in 95 articles.  
Exclusions included reviews, expert opinions, and those without abstracts.  Inclusions were meeting 
presentations and QoL as a secondary outcome written in English or Spanish, from 2016 to 2020.   QoL 
measures include validated severity assessment tools, SCORing AD (SCORAD), Patient-Oriented Eczema 
measure (POEM), Patient-Oriented SCORAD (PO-SCCORAD), (Children’s) Dermatology Life Quality Index 
(C) DLQI, and Severity of Pruritus Scale (0-3).   
Results 
Crisaborole treatment improved CDLQI and DLQI scores in 2 multicenter, double-blind, vehicle-
controlled Phase 3 studies in AD patients older than 2 years.  Post-hoc mediation modeling of the 
studies suggests that QoL improvement was due primarily to an early reduction in pruritis.  Pooled post-
hoc analysis of the efficacy and safety of Crisaborole according to race and ethnicity reported improved 
QoL measures across all age and race/ethnic categories.   
Conclusion 
Compromised QoL related to mild to moderate AD poses a significant public health burden.  Although 
more studies assessing the effect of Crisaborole on QoL in different populations are needed, available 
studies suggest that Crisaborole offers a promising treatment option in which QoL is prioritized.  
Furthermore, given the complexity of the disease and inconsistencies in treatment guidelines across 
healthcare disciplines, the addition of Crisaborole, a choice with fewer side effects than other topical 
agents, offers a path to improving QoL in those affected with mild to moderate AD.    
